ClinicalTrials.gg
Enrolling by invitationNCT07116668SAFE-3CVUpdated Apr 29, 2026

SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study

An interventional study of Colovac Anastomosis Protection Device placement following low anterior resection of colon cancer in Colorectal Cancer and Stoma - Ileostomy, sponsored by SafeHeal Inc. Enrolling by invitation at 18 sites in 4 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by SafeHeal Inc · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
756th of 1,934
108 · median 64
Started
2026
with 119 others
No phase
533 of 2,342
93 open now
Primary completion
2026-12
later than 139 of 627 live
Registered
2,186th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 756th largest by planned enrollment of the 1,934 interventional ones that give a count, is one of 120 that started in 2026, is one of 533 with no phase, reaches primary completion later than 139 of the 627 other live ones, and was the 2,186th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Colorectal cancer is the third most common malignancy worldwide and the second most common in the US. It is the second leading cause of cancer death worldwide, with 1.8 million new cases and 862,000 deaths per year. The majority of patients receive surgical treatment. Colorectal surgery is associated with a high risk of morbidity and mortality in comparison to other general surgery subspecialties. This study aims to further assess the safety and effectiveness of the Colovac Anastomosis Protection Device, a temporary intraluminal bypass device, on a larger scale.

Read the detailed description

The Colovac Anastomosis Protection Device is intended for use in patients requiring low anterior rectal anastomoses to limit stoma creation to only those patients requiring more time for anastomosis healing when the device is removed, allowing patients with a healed anastomosis to avoid stoma creation. To reduce the risk of life-threatening complications, Colovac provides an alternative to stoma creation which prevents stoma related risks, including permanent stoma.

03

Conditions studied

  • Colorectal Cancer
  • Stoma - Ileostomy
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject meeting all of the following criteria will be considered for participation in the study:

  1. Adult patients (22 years of age or older)
  2. Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for .
  3. (ECOG) Performance Status ≤ 2
  4. Willingness to comply with protocol-specific treatment and study visits and to sign a written Form

Exclusion criteria

Exclusion Criteria:

  • Preoperative:

    1. Active colitis
    2. Known allergy to nickel or other components of the Colovac system
    3. Pregnant or nursing female subject
    4. Concomitant major surgical procedure in combination with Colorectal resection (i.e., hepatectomy)
    5. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo protocol-described procedures or interfere with the interpretation of study results including, but not limited to:

      1. Stage IV colorectal cancer unless curative intent R0 resection is planned AND there is no associated peritoneal disease
      2. Immunodeficiency ( \< 500 CU MM)
      3. Systemic and ongoing therapy within the past 6 months
      4. Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery
      5. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study
      6. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, or carcinomatosis
      7. Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging
      8. Severe malnutrition defined as 10% weight loss within 3 months prior to enrollment.
    6. The subject is currently participating in another drug or device study that may confound the results of SAFE-3CV. Prior approval from SafeHeal Medical Monitor must be obtained prior to enrollment in SAFE-3CV.

      Intraoperatively:

    7. Occurrence of any of the following during the colorectal surgery:

      1. Blood loss (>750 cc)
      2. Blood transfusion
      3. Any new sign of bowel ischemia
      4. Positive air leak test
      5. Inadequate bowel preparation
      6. Anastomosis location greater than 10 cm from the anal verge
      7. Any other surgical complications or intra-operative risks that may place the patient at greater risk from study procedures
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Colovac arm

    Subjects treated with the Colovac Device following low anterior resection of the colon will be enrolled in the investigational cohort.

    Device: Colovac Anastomosis Protection Device placement following low anterior resection of colon cancer

Interventions

  • DeviceColovac Anastomosis Protection Device placement following low anterior resection of colon cancer

    Subjects in the Investigational cohort (SAFE-3CV) will undergo an LAR procedure followed by Colovac placement. Colovac retrieval will then occur at \~10 days post LAR procedure.

06

What researchers measure

Primary outcomes

  1. Performance: Clinically meaningful ostomy avoidance rate at Day 10

    The primary performance endpoint assessed for Colovac subjects at the Day 10 visit is a clinically meaningful ostomy avoidance rate that supports a favorable benefit risk when considering the primary safety endpoint.

    Time frame: at 10 day visit

  2. Safety: Cumulative rate of Major Complications

    The primary safety endpoint is the cumulative rate of subjects with major complications through 9 months.

    Time frame: 9 months

07

Study locations

18 sites
08

References and documents

Publications

  • Pastier C, Sylla P, Lee SW, Spinelli A, Komen N, Marks J, Martz J, Rhee R, Maykel J, Marcet J, Denost Q, Zaghiyan K, Davids JS, Paluvoi N, Hiller D, McLemore EC, Maggiori L, D'hoore A, Jafari MD, Poylin V, Buzas CJ, Tuech JJ, Lefevre JH. Safety and effectiveness of the Colovac anastomosis protection device compared with diverting ileostomy after low anterior resection: protocol for an international, multicentre, prospective, non-randomised comparative study (SAFE-3). BMJ Open Gastroenterol. 2026 Jun 12;13(1):e002235. doi: 10.1136/bmjgast-2025-002235. PubMed 42285586 ↗

Individual participant data

Plan to share: No — The data is confidential and only available upon a reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's planned 11 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 11, 2025
StartActual
Jan 8, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07116668
Lead sponsor
SafeHeal Inc
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Jan 8, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Apr 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion